Abstracts tagged "B cells"

Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting
Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Asiya Chida¹, Kevin Cashman¹, Scott Jenks², Louise Hartson¹, Youliang Wang¹, Quan-Zhen Li Li^3,4, Chandra Mohan⁵ and Ignacio Sanz^6,7, ¹Medicine, Emory University, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Biomedical Engineering, University of Houston, Houston, TX, ⁶Rheumatology, Emory University, Atlanta, GA, ⁷Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…
Abstract Number: 1922 • 2015 ACR/ARHP Annual Meeting
Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis
Nicolas Dumoitier^1,2,3,4, Sebastien Lofek^2,3,5, Alexis Regent⁶, Jonathan London⁷, Benjamin Chaigne^1,2,3,8, Benjamin Terrier^2,7,9,10, Nadine Varin-Blank^4,11 and Luc Mouthon^1,2,4,6, ¹Infection, Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ²CNRS, UMR8104, Paris, France, ³Université Paris Descartes, Paris, France, ⁴Labex Inflamex, Université Sorbonne Paris Cité, Paris, France, ⁵Infection,Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁷Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁸Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochinl, Paris, France, ⁹Infection, Immunité, Inflammation, Institut Cochin INSERM U1016, Paris, France, ¹⁰Université Paris Descartes, paris, France, ¹¹UFR SMBH, INSERM, UMR978, Bobigny, France
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by fibroblasts activation, increased extra-cellular matrix synthesis associated with autoimmunity. However, the potential role…
Abstract Number: 2820 • 2014 ACR/ARHP Annual Meeting
Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation
Nida Meednu¹, Hengwei Zhang², Teresa Owen³, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…
Abstract Number: 1943 • 2014 ACR/ARHP Annual Meeting
In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Carolin Brandl*¹, Lamia Özgör*¹, Miriam Wöhner^1,2, Anthony Shock³ and Lars Nitschke¹, ¹Division of Genetics, University of Erlangen, Erlangen, Germany, ²Research Institute of Molecular Pathology, Vienna, Austria, ³UCB Pharma, Slough, United Kingdom
Background/Purpose Epratuzumab is a humanized monoclonal antibody that targets the B cell-specific protein CD22 currently in Phase 3 clinical trials in patients (pts) with systemic…
Abstract Number: 994 • 2014 ACR/ARHP Annual Meeting
IL-7 Modulates B Cell Immunoglobulin Isotype Production and Increases B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Synovial Fibroblasts from Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients
Georg Pongratz¹, Stephan Kuhn², Madlen Melzer², Torsten Lowin² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Interleukin(IL)-7 is increased in synovial fluid from rheumatoid arthritis (RA) patients as compared to osteoarthritis (OA) patients and has been attributed a proinflammatory role,…
Abstract Number: 2806 • 2014 ACR/ARHP Annual Meeting
Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls
Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose : IgG4-related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4-positive plasma cells and T cells into various organs.…
Abstract Number: 1942 • 2014 ACR/ARHP Annual Meeting
Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark⁴, ¹Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom, ⁴Department of Immunology and Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose The B cell-associated receptor, CD22, functions to regulate adhesion and signaling through both the B cell receptor (BCR) and Toll-like receptors (TLRs) expressed in…
Abstract Number: 992 • 2014 ACR/ARHP Annual Meeting
Differential Antigen-Presenting B-Cell Phenotype from Synovial Microenvironment of Rheumatoid Arthritis and Psoriatic Arthritis Patients
Estefania Armas-Gonzalez¹, Ana Diaz-Martin¹, María Jesús Dominguez-Luis², Maria Teresa Arce-Franco¹, Ada Herrera-Garcia¹, Vanesa Hernandez¹, Alicia Usategui³, Jose L. Pablos⁴, Juan D. Cañete⁵, Sagrario Bustabad¹ and Federico Díaz-González¹, ¹Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Center of Biomedical Research of the Canary Islands, University of La Laguna, Tenerife, Spain, ³Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁴Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁵Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose The systemic depletion of B cells induced by mabthera, a monoclonal antibody against human CD20, has shown to be an effective therapy for controlling…
Abstract Number: 2696 • 2014 ACR/ARHP Annual Meeting
Relationship Between Soluble sCD23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab
Laura Heretiu^1,2, Maria J. Leandro³, Venkat Reddy⁴, David A. Isenberg⁵ and Geraldine Cambridge³, ¹Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Rheumatology and Internal Medicine, 'Sf. Maria' Clinical Hospital, Bucharest, Romania, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose CD23 is the low-affinity receptor for IgE (FceRII). The soluble form, sCD23 is released into the circulation and in vitro this is consistent with…
Abstract Number: 1941 • 2014 ACR/ARHP Annual Meeting
Neuropsychiatric Lupus Is Substantially Unaffected By B-Cell Deficiency
Jing Wen¹, Ariel Stock², Haowei Wang³, Mark Shlomchik³, Maria Gulinello² and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric lupus (NPSLE) is one of the earliest clinical manifestations in human lupus. However, its mechanisms are not fully understood. In lupus, a compromised…
Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting
The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis
Cecile Gamonet¹, Marina Deschamps², Sandrine Marion³, Philippe Saas⁴, Gilles Chioccha³, Christophe Ferrand⁴ and Eric Toussirot^5,6, ¹INSERM UMR1098, Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ²INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, ³Chronic Inflammation and Immune System Labex Inflamex, Université Versailles Saint Quentin, Montigny le Bretonneux, France, ⁴Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁵Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ⁶Rheumatology, University hospital, Besançon, France
Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…
Abstract Number: 2695 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo¹, David P. D'Cruz² and Jo Spencer³, ¹Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA) are autoimmune diseases which develop secondary to immune self-tolerance failure. Both diseases are characterised in…
Abstract Number: 1940 • 2014 ACR/ARHP Annual Meeting
A Novel Murine Model of B Cell-Mediated Glomerular Injury Is Mediated By Cytokines
Alfred Kim¹, Shreeram Akilesh², Ania Koziell³, Sanjay Jain⁴, Jeffrey Hodgin⁵, Mark Miller⁶, Jeffrey Miner⁴ and Andrey Shaw⁷, ¹IM/Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ²Pathology & Immunolog, Washington University School of Medicine, Saint Louis, MO, ³Experimental Immunobiology, King's College, London, United Kingdom, ⁴Renal Division, Washington University School of Medicine, Saint Louis, MO, ⁵Nephrology, University of Michigan, Ann Arbor, MI, ⁶Infectious Diseases, Washington University School of Medicine, Saint Louis, MO, ⁷Pathology & Immunology/HHMI, Washington University School of Medicine, Saint Louis, MO
Background/Purpose Lupus nephritis (LN) remains the leading cause of mortality for SLE patients, and is associated with proteinuria and foot process effacement. Podocyte foot process effacement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].